What SR One Capital Management, LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1910264 · Filed Aug 12, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 5M |
| ±0% |
| $127.9M |
| 12.3% |
CRSPCRISPR Therapeutics AG | 2M | ±0% | $111.2M | 10.7% |
AVLNAvalyn Pharma Inc. | 3.3M | New | $108.9M | 10.5% |
DSGNDesign Therapeutics, Inc. | 6.5M | ±0% | $94.4M | 9.1% |
ODTXOdyssey Therapeutics, Inc. | 3.8M | New | $71M | 6.8% |
ALMSAlumis Inc. | 2M | ±0% | $55.2M | 5.3% |
ORICOric Pharmaceuticals, Inc. | 4.6M | +2.2% | $50M | 4.8% |
MLYSMineralys Therapeutics, Inc. | 1.6M | ±0% | $42.2M | 4.1% |
SPRYARS Pharmaceuticals, Inc. | 4M | ±0% | $32.1M | 3.1% |
MOBIMobia Medical, Inc. | 2M | New | $26.6M | 2.6% |
NKTXNkarta, Inc. | 3.3M | ±0% | $9.4M | 0.9% |
OCSOculis Holding AG | 641K | ±0% | $8.9M | 0.9% |
RAREUltragenyx Pharmaceutical Inc. | 137.8K | ±0% | $4.6M | 0.4% |
ENGNenGene Therapeutics Inc. | 747.8K | ±0% | $1.3M | 0.1% |
